"Efficacy and Tolerability of Long-Acting Injectable Formulation of Nalmefene (Nalmefene Consta 393.1 mg) for Opioid Relapse Prevention: A Multicentre, Open-Label, Randomised Controlled Trial"
written by Sead Kadric, Hanns Mohler, Olli Kallioniemi, Karl Heinz Altmann,
published by World Journal of Neuroscience, Vol.9 No.3, 2019
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
No relevant information.